Protocol Ledger

NCT04257929 · Phase II · COMPLETED

A Phase 2 Study to Evaluate the Safety and Efficacy of Pitolisant in Patients With Prader-Willi Syndrome, Followed by an Open Label Extension

Interventional Phase II clinical trial protocol NCT04257929 sponsored by Harmony Biosciences Management in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-12-09 Enrollment: 65 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04257929
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)65 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04257929
Protocol FieldVerified Registry Value
NCT IdentifierNCT04257929
Consolidated Lead SponsorHarmony Biosciences Management
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment65 participants (ACTUAL)
Registered Start Date2020-12-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI